Ssengooba Willy, Musisi Emmanuel, Semugenze Derrick, Komakech Kevin, Ndema Moses, Sekaggya Christine Wiltshire, Adakun Susan, Sloan Derek J, Katamba Achilles, Lamorde Mohammed, Joloba Moses, Sabiiti Wilber
Department of Medical Microbiology, and Makerere University Biomedical Research Center (MAKBRC), College of Health Sciences Makerere University.
Division of Infection and Global Health, School of Medicine, University of St Andrews, KY16 9TF St Andrews.
Res Sq. 2025 Apr 10:rs.3.rs-5834681. doi: 10.21203/rs.3.rs-5834681/v1.
Monitoring response to Multi-Drug-Resistant Tuberculosis (MDR-TB) treatment is burdensome to TB programmes and may benefit from alternative effective tools. We evaluated the concordance of alternative bacteriological measures of response to therapy (AMRT) during the initial sixteen weeks of MDR-TB treatment.
In a prospective study of MDR/RR-TB among smear positive adults, aged 18 year and above. Pooled early morning- and spot sputa were obtained before treatment initiation (95% on Bdq, Lzd, Lfx, Cfz, Cs regimen) and at weeks 2, 4, 6, 8, 12, and 16 during treatment between 14/02/2020 and 09/02/2024. Samples were tested using Concentrated Fluorescent Microscopy (CFM), Fluorescein-diacetate (FDA)-Acid Fast Bacilli (AFB) vital smear microscopy, the tuberculosis-Molecular bacterial load assay (TB-MBLA), and Middle brook 7H11 selective (MB7H11S) colony-forming units as the AMRT. Concordance of the AMRT for sputum conversion was compared to Mycobacterial Growth Indicator Tube (MGIT) culture conversion at weeks 12 and 16 of treatment.
A total of 101 MDR/RR-TB patients were screened of which 42 were smear negative. Fifty-nine participants were enrolled, of whom 58 (98%) provided baseline sputa and these were included in the analysis. The concordance, n/N (%) of each AMRT test with MGIT culture conversion at week 12 were: 31/35(88.6%) for CFM, 32/33 (97.0%) for FDA, and 25/26 (96.2%) for TB-MBLA, and 11/11 (100%) for MB7H11S. At week 16, concordance of eachAMRT were: 39/40 (97.5%) for CFM, 35/36 (97.2%) for FDA, 32/32 (100%) for TB-MBLA, and 15/15 (100%) for MB7H11S. Among people living with HIV,the concordances of AMRT with MGIT culture conversion varied at week 8 but was 100% for all tests at weeks 12 and 16. Baseline clinical and/or bacteriological factors did not influence the concordance of AMRT to MGIT culture conversion at weeks 12, and 16.
Our data show that concentrated Fluorescent smear, Fluorescein-di-acetate smear microscopy, and TB-MBLA are suitable alternative measures of response to TB therapy compared to MGIT culture among MDR-TB participants. Use of these alternative rapid methods may allow timely decision making as well as rapid evaluation of alternative MDR-TB treatment regimens.
监测耐多药结核病(MDR-TB)治疗反应对结核病防治项目来说负担沉重,而采用替代有效工具可能会有所助益。我们评估了耐多药结核病治疗最初16周期间治疗反应替代细菌学测量方法(AMRT)的一致性。
在一项针对18岁及以上涂片阳性成年耐多药/利福平耐药结核病(MDR/RR-TB)患者的前瞻性研究中。在治疗开始前(95%采用Bdq、Lzd、Lfx、Cfz、Cs方案)以及2020年2月14日至2024年2月9日治疗期间的第2、4、6、8、12和16周采集合并的清晨痰和即时痰。使用浓缩荧光显微镜检查(CFM)、荧光素二乙酸酯(FDA)-抗酸杆菌(AFB)活菌涂片显微镜检查、结核病-分子细菌载量测定(TB-MBLA)以及Middle brook 7H11选择性(MB7H11S)菌落形成单位作为AMRT对样本进行检测。将治疗第12周和第16周时AMRT痰菌转阴的一致性与分枝杆菌生长指示管(MGIT)培养转阴情况进行比较。
共筛查了101例耐多药/利福平耐药结核病患者,其中42例涂片阴性。纳入了59名参与者,其中58名(98%)提供了基线痰液样本并纳入分析。在第12周时,每种AMRT检测与MGIT培养转阴的一致性,n/N(%)分别为:CFM为31/35(88.6%),FDA为32/33(97.0%),TB-MBLA为25/26(96.2%),MB7H11S为11/11(100%)。在第16周时,每种AMRT的一致性分别为:CFM为39/40(97.5%),FDA为35/36(97.2%),TB-MBLA为32/32(100%),MB7H11S为15/15(100%)。在艾滋病毒感染者中,第8周时AMRT与MGIT培养转阴的一致性有所不同,但在第12周和第16周时所有检测的一致性均为100%。基线临床和/或细菌学因素在第12周和第16周时并未影响AMRT与MGIT培养转阴的一致性。
我们的数据表明,与MGIT培养相比,浓缩荧光涂片、荧光素二乙酸酯涂片显微镜检查以及TB-MBLA是耐多药结核病参与者结核病治疗反应的合适替代测量方法。使用这些替代快速方法可能有助于及时做出决策,并能快速评估替代耐多药结核病治疗方案。